BTIG Research Reaffirms Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM)

Cullinan Therapeutics (NASDAQ:CGEM)‘s stock had its “buy” rating reissued by equities research analysts at BTIG Research in a research note issued on Friday, Benzinga reports. They presently have a $40.00 target price on the stock. BTIG Research’s price target suggests a potential upside of 158.73% from the company’s current price.

CGEM has been the subject of several other reports. HC Wainwright raised their price target on Cullinan Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Friday. TD Cowen upgraded Cullinan Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Wedbush raised their target price on Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Wall Street Zen lowered shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.71.

Cullinan Therapeutics Price Performance

NASDAQ:CGEM opened at $15.46 on Friday. The firm has a market cap of $995.01 million, a price-to-earnings ratio of -4.93 and a beta of 0.02. The firm’s fifty day moving average price is $19.83 and its 200 day moving average price is $16.71. Cullinan Therapeutics has a 1-year low of $5.68 and a 1-year high of $23.19.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.01). As a group, analysts expect that Cullinan Therapeutics will post -3.08 earnings per share for the current fiscal year.

Insider Transactions at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 30,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $20.26, for a total value of $607,800.00. Following the sale, the insider owned 162,844 shares of the company’s stock, valued at $3,299,219.44. This represents a 15.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 46,000 shares of company stock worth $922,920 in the last ninety days. Insiders own 8.60% of the company’s stock.

Institutional Trading of Cullinan Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CGEM. Integrated Wealth Concepts LLC purchased a new stake in shares of Cullinan Therapeutics in the second quarter valued at about $25,000. Seven Fleet Capital Management LP purchased a new stake in shares of Cullinan Therapeutics in the fourth quarter valued at about $31,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Cullinan Therapeutics by 181.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,680 shares of the company’s stock valued at $48,000 after purchasing an additional 3,020 shares in the last quarter. Allworth Financial LP purchased a new stake in shares of Cullinan Therapeutics in the second quarter valued at about $53,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Cullinan Therapeutics in the second quarter valued at about $53,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics News Roundup

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $40 price target, implying substantial upside from the recent trading level. This indicates the firm believes Cullinan’s pipeline is undervalued. BTIG Research rating and price target
• Positive Sentiment: Cullinan outlined multiple fourth-quarter 2026 data catalysts, including velinotamig multi-dose data in systemic lupus erythematosus at the November ACR Convergence meeting, plus CLN-978 data in lupus, rheumatoid arthritis and Sjögren’s disease and updated CLN-049 Phase 1 data in December. Cullinan Therapeutics fourth-quarter pipeline milestones
• Neutral Sentiment: The company’s broader T-cell engager pipeline remains the main source of potential value, with clinical updates planned across three programs. The impact will depend on the quality and durability of the forthcoming data. Cullinan Therapeutics T-cell engager milestones
• Negative Sentiment: Cullinan delayed an early-stage clinical update for its arthritis therapy until December. The postponement removes a near-term catalyst and has increased investor uncertainty regarding the program’s progress. Cullinan delays arthritis therapy data
• Negative Sentiment: Although recent Phase 3 zipalertinib data for lung cancer were described as strong, investor concerns about the drug’s safety profile remain. Those concerns have overshadowed the efficacy data and contributed to the stock’s decline. CGEM losses and zipalertinib safety concerns

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.